
Tatva Chintan Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 2- SDA segment volume expected to grow nearly 50% in FY25 with 25% revenue growth due to raw material price reductions; further 30-40% volume growth expected in FY26 driven by Euro 7 implementation.
- Electrolyte Salts revenue projected to increase by around 150-160% in FY25.
- PASC segment anticipated to grow 80-90% in FY25, with commercial production started for some products.
- Phase Transfer Catalysts (PTC) expected to grow 8-10% in FY25 despite price declines.
- New automotive customers expected to contribute significant volumes, with roughly 15% of their existing business volume expected in FY25; relationship build-up may take a couple of years.
- Capacity constraints anticipated by end-FY25 with utilization reaching 85-90%; CAPEX of Rs.70 crore planned to expand capacity.
- Long-term growth seen from innovative products and new site plant expansion despite some delays due to soil testing.
See what Tatva Chintan management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned new fundraising through debt or equity in the earnings call transcript.
- The company has fully utilized its net IPO proceeds of ₹2,072.81 million as of 31 March 2024.
- The transcript focuses on operational updates, capacity expansion plans, and expected revenue growth but does not indicate plans for additional capital raising.
- CAPEX for FY25 and FY26 is planned at around ₹70 crores, to be funded from internal accruals, with no equity or debt fundraising mentioned.
- Soil testing issues have delayed new plant construction but no mention of raising funds to resolve this.
- Overall, no new debt or equity fundraising is disclosed for immediate or near-future needs.
See what Tatva Chintan management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned CAPEX for FY25 and FY26 is around Rs. 70 crores.
- CAPEX was delayed due to unfavorable soil test results at the identified site for a multi-story plant.
- The company is testing three alternative sites; if unsuitable, may scale down plant from 7 floors to 4 floors.
- The new plant is critical to address capacity constraints expected by FY26.
- Additional investments include setting up a solvent recovery & distillation plant (commissioning by May-June) and a bromine recovery plant (by August-September).
- Waste treatment setups are being considered within existing premises to optimize plant utilization.
- The company aims for a multi-story building with maximum reactors for future growth but is flexible based on soil test outcomes.
Track Tatva Chintan — get its next earnings analysis in your feed
How does Tatva Chintan rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Tatva Chintan rank in Chemicals & Petrochemicals?
Compare Tatva Chintan against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Tatva Chintan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…